NASDAQ:BBLG Bone Biologics (BBLG) Stock Price, News & Analysis $0.59 -0.01 (-2.28%) As of 01:55 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Bone Biologics Stock (NASDAQ:BBLG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bone Biologics alerts:Sign Up Key Stats Today's Range$0.58▼$0.5950-Day Range$0.60▼$1.4752-Week Range$0.58▼$4.13Volume56,550 shsAverage Volume140,005 shsMarket Capitalization$1.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Bone Biologics, Inc. (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells. Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects. Early-stage clinical studies and preclinical investigations are underway to assess safety, tolerability and preliminary efficacy in these high-need segments. The company collaborates with leading orthopedic surgeons and academic centers to design protocols and gather real-world insights that may inform future pivotal trials. Founded in the late 2010s and headquartered in New Jersey, Bone Biologics has assembled a leadership team with extensive experience in regenerative medicine, cell therapy manufacturing and orthopedic clinical development. The company maintains partnerships with contract development and manufacturing organizations to scale its cell production processes, while engaging regulatory consultants to support filings with health authorities. As a dedicated cell therapy innovator, Bone Biologics aims to address significant unmet needs in bone repair and establish new standards for patient outcomes in orthopedic care.AI Generated. May Contain Errors. Read More Bone Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreBBLG MarketRank™: Bone Biologics scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBone Biologics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBone Biologics has only been the subject of 1 research reports in the past 90 days.Read more about Bone Biologics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Bone Biologics are expected to grow in the coming year, from ($1.23) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bone Biologics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bone Biologics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBone Biologics has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Bone Biologics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.02% of the float of Bone Biologics has been sold short.Short Interest Ratio / Days to CoverBone Biologics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bone Biologics has recently increased by 646.34%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBone Biologics does not currently pay a dividend.Dividend GrowthBone Biologics does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment-0.93 News SentimentBone Biologics has a news sentiment score of -0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Bone Biologics this week, compared to 2 articles on an average week.Search Interest1 people have searched for BBLG on MarketBeat in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bone Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders5.60% of the stock of Bone Biologics is held by insiders.Percentage Held by Institutions34.30% of the stock of Bone Biologics is held by institutions.Read more about Bone Biologics' insider trading history. Receive BBLG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bone Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBLG Stock News HeadlinesZacks Research Cuts Earnings Estimates for Bone BiologicsAugust 22, 2026 | americanbankingnews.comBBLG Efficiency Improves as Crucial Trials AdvanceAugust 17, 2026 | finance.yahoo.comTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security. The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move.August 26 at 1:00 AM | Porter & Company (Ad)Bone Biologics extends rhNELL-1 validated shelf life to 32 months as NB1 study advancesAugust 12, 2026 | msn.comBone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1August 12, 2026 | globenewswire.comBone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 PrioritiesJuly 23, 2026 | globenewswire.comBBLG Secures Financing for Critical TrialsJuly 8, 2026 | finance.yahoo.comBONE BIOLOGICS CORPORATION: Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesJuly 8, 2026 | finanznachrichten.deSee More Headlines BBLG Stock Analysis - Frequently Asked Questions How have BBLG shares performed this year? Bone Biologics' stock was trading at $1.45 on January 1st, 2026. Since then, BBLG shares have decreased by 59.5% and is now trading at $0.5870. How were Bone Biologics' earnings last quarter? Bone Biologics Corp. (NASDAQ:BBLG) issued its quarterly earnings results on Friday, August, 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.04. When did Bone Biologics' stock split? Bone Biologics shares reverse split on Tuesday, June 10th 2025.The 1-6 reverse split was announced on Monday, June 9th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 9th 2025. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. When did Bone Biologics IPO? Bone Biologics (BBLG) raised $8 million in an initial public offering (IPO) on Wednesday, October 13th 2021. The company issued 1,510,455 shares at a price of $5.25 per share. How do I buy shares of Bone Biologics? Shares of BBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bone Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bone Biologics investors own include Pfizer (PFE), NVIDIA (NVDA), Meta Platforms (META), PayPal (PYPL), Advanced Micro Devices (AMD), Canopy Growth (CGC) and Cisco Systems (CSCO). Company Calendar Last Earnings8/14/2026Today8/26/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (12m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 BBLG's financial health is in the Red zone, according to TradeSmith. BBLG has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:BBLG Previous SymbolNASDAQ:BBLG CIK1419554 Webwww.bonebiologics.com Phone781-552-4452FaxN/AEmployees2Year Founded2004Profitability EPS (Trailing Twelve Months)($1.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.11 million Net MarginsN/A Pretax MarginN/A Return on Equity-57.87% Return on Assets-53.65% Debt Debt-to-Equity RatioN/A Current Ratio8.67 Quick Ratio8.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book0.42Miscellaneous Outstanding Shares2,760,000Free Float2,602,000Market Cap$1.63 million OptionableNot Optionable Beta0.92 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:BBLG) was last updated on 8/26/2026 by MarketBeat.com Staff. From Our PartnersA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredTrump Unleashes "Banned" American FuelA newly reopened American mine holds a fuel source so potent that one pound can generate as much energy as 16,...Monument Traders Alliance | SponsoredThe New Kings of CantillonIn 1720, Richard Cantillon discovered that new money never spreads evenly through an economy. It reaches certa...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bone Biologics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bone Biologics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BBLG Stock Alerts